Comparison of Serum Ordinala Hemagglutination Inhibition Antibody Levels Against 2009 Influenza A(H1N1) Pandemic Virus Among 834 Healthcare Personnel With Preseason, Post–Trivalent Inactivated Vaccine, and End-of-Season Serum Samples in 2010–2011 From the Linear Mixed-Effects Model, by Vaccination Status
| Comparison Between Groups . | Mean Difference Estimate . | Standard Error . | P Value . | GMT Ratio Estimate (95% CI)b . |
|---|---|---|---|---|
| MIIV vs No prior MIIV on day of receipt of 2010–2011 TIVc | 1.2056 | 0.1368 | <.0001 | 2.31 (1.92–2.78) |
| MIIV vs No MIIV 31d days post-TIV | −0.8088 | 0.1373 | <.0001 | 0.57 (.47–.69) |
| MIIV vs No MIIV 198e days post-TIV | −0.4383 | 0.1398 | .0017 | 0.74 (.61–.89) |
| Comparison Between Groups . | Mean Difference Estimate . | Standard Error . | P Value . | GMT Ratio Estimate (95% CI)b . |
|---|---|---|---|---|
| MIIV vs No prior MIIV on day of receipt of 2010–2011 TIVc | 1.2056 | 0.1368 | <.0001 | 2.31 (1.92–2.78) |
| MIIV vs No MIIV 31d days post-TIV | −0.8088 | 0.1373 | <.0001 | 0.57 (.47–.69) |
| MIIV vs No MIIV 198e days post-TIV | −0.4383 | 0.1398 | .0017 | 0.74 (.61–.89) |
Abbreviations: CI, confidence interval; GMT, geometric mean titer; MIIV, 2009–2010 A(H1N1) pandemic monovalent inactivated influenza vaccine; TIV, trivalent inactivated vaccine.
a Ordinal hemagglutination inhibition antibody (HI) levels are represented with 0–9 levels based on log transformation of HI titers: Log2 (HI titer/5).
b GMT ratio estimate was calculated by 2 to the power of mean difference estimate. The 95% CI was calculated by 2 to the power of mean difference estimate ± 1.96 × Standard Error.
c Day 0: date of receipt of 2010–2011 TIV (used as proxy for preseason, adjusting for days from preseason serum to TIV receipt).
d Day 31: mean number of days from 2010–2011 TIV to post-TIV serum.
e Day 198: mean number of days from 2010–2011 TIV to end-of-season serum.
Comparison of Serum Ordinala Hemagglutination Inhibition Antibody Levels Against 2009 Influenza A(H1N1) Pandemic Virus Among 834 Healthcare Personnel With Preseason, Post–Trivalent Inactivated Vaccine, and End-of-Season Serum Samples in 2010–2011 From the Linear Mixed-Effects Model, by Vaccination Status
| Comparison Between Groups . | Mean Difference Estimate . | Standard Error . | P Value . | GMT Ratio Estimate (95% CI)b . |
|---|---|---|---|---|
| MIIV vs No prior MIIV on day of receipt of 2010–2011 TIVc | 1.2056 | 0.1368 | <.0001 | 2.31 (1.92–2.78) |
| MIIV vs No MIIV 31d days post-TIV | −0.8088 | 0.1373 | <.0001 | 0.57 (.47–.69) |
| MIIV vs No MIIV 198e days post-TIV | −0.4383 | 0.1398 | .0017 | 0.74 (.61–.89) |
| Comparison Between Groups . | Mean Difference Estimate . | Standard Error . | P Value . | GMT Ratio Estimate (95% CI)b . |
|---|---|---|---|---|
| MIIV vs No prior MIIV on day of receipt of 2010–2011 TIVc | 1.2056 | 0.1368 | <.0001 | 2.31 (1.92–2.78) |
| MIIV vs No MIIV 31d days post-TIV | −0.8088 | 0.1373 | <.0001 | 0.57 (.47–.69) |
| MIIV vs No MIIV 198e days post-TIV | −0.4383 | 0.1398 | .0017 | 0.74 (.61–.89) |
Abbreviations: CI, confidence interval; GMT, geometric mean titer; MIIV, 2009–2010 A(H1N1) pandemic monovalent inactivated influenza vaccine; TIV, trivalent inactivated vaccine.
a Ordinal hemagglutination inhibition antibody (HI) levels are represented with 0–9 levels based on log transformation of HI titers: Log2 (HI titer/5).
b GMT ratio estimate was calculated by 2 to the power of mean difference estimate. The 95% CI was calculated by 2 to the power of mean difference estimate ± 1.96 × Standard Error.
c Day 0: date of receipt of 2010–2011 TIV (used as proxy for preseason, adjusting for days from preseason serum to TIV receipt).
d Day 31: mean number of days from 2010–2011 TIV to post-TIV serum.
e Day 198: mean number of days from 2010–2011 TIV to end-of-season serum.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
